TY  - GEN
N2  - FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.
DO  - http://dx.doi.org/10.5771/9783845294018
DO  - doi
AB  - FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.
T1  - FTO (Freedom to Operate) in the Pharmaceutical Industry /
AU  - Nonaka, Hirotaka
ET  - 1st ed.
LA  - eng
N1  - This resource was extracted from the Directory of Open Access Books (DOAB)
ID  - 41676
KW  - Intellectual property
KW  - EU competition law
KW  - Pharmaceutical industry
KW  - License
SN  - 9783845294018
TI  - FTO (Freedom to Operate) in the Pharmaceutical Industry /
LK  - https://www.doabooks.org/doab?func=search&query=rid%3A29406
UR  - https://www.doabooks.org/doab?func=search&query=rid%3A29406
ER  -